Publisher
Springer Science and Business Media LLC
Subject
Endocrinology,Endocrinology, Diabetes and Metabolism
Reference74 articles.
1. G.M. Clark, Prognostic factors versus predictive factors: Examples from a clinical trial of erlotinib. Mol. Oncol. 1, 406–412 (2008)
2. G.M. Clark, D.M. Zborowski, J.L. Culbertson, M. Whitehead, M. Savoie, L. Seymour, F.A. Shepherd, Clinical utility of epidermal growth factor receptor expression for selecting patients with advanced non-small cell lung cancer for treatment with erlotinib. J. Thorac. Oncol. 1, 837–846 (2006)
3. K.G. Moons, P. Royston, Y. Vergouwe, D.E. Grobbee, D.G. Altman, Prognosis and prognostic research: what, why, and how? BMJ 338, b375 (2009)
4. R.D. Riley, J.A. Hayden, E.W. Steyerberg, K.G. Moons, K. Abrams, P.A. Kyzas, N. Malats, A. Briggs, S. Schroter, D.G. Altman, H. Hemingway; PROGRESS Group, Prognostic research strategy (PROGRESS) 2: prognostic factor research. PLoS Med. 10, e1001380 (2013)
5. A. Vijayaraghavan, M.B. Efrusy, B. Goke, T. Kirchner, C.C. Santas, R.M. Goldberg, Cost-effectiveness of KRAS testing in metastatic colorectal cancer patients in the United States and Germany. Int. J. Cancer 131, 438–445 (2012)
Cited by
10 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献